Advances and Progress in Drug Design 2015
Date: | 16-Feb-15 to 17-Feb-15 |
Location: | Marriott Hotel Regents Park / London / United Kingdom |
Category: | Healthcare & Pharmaceuticals Science Conferences & Trade Fairs World & Regional |
SMi are proud to present the 14th annual conference, Advances and Progress in Drug Design, taking place on 16th & 17th February 2015 in Central London.
Join us as we ask questions such as: What are the key challenges in biotherapeutics discovery? How have computational and predictive tools matured for the application of drug discovery? Are there novel ways to inhibit kinase targets? How can we successfully apply ligand-based and structure based computational approaches for the rational design of novel GPCR antagonists? What are the best approaches in building a robust technology pipeline for robust fragment based drug discovery?
Hear case study driven presentations from an array of market leaders such as the University of Cambridge, Janssen, MedImmune, Sanofi and Novartis, discussing computational approaches, structure based drug design, pharmacokinetics, polypharmacology, drug metabolism and fragment based drug design, PLUS MUCH MORE!
KEY REASONS TO JOIN:
• DISCUSS the application of computational based drug design with five presentations focusing on modelling and engineering
• JOIN the panel discussion on computational and predictive tools for the application of drug discovery
• ENHANCE your understanding of fragment-based drug design by listening to presentations led by UCB Pharmaceuticals, Astex Pharmaceuticals, ZoBio and the University of Birmingham
• LISTEN to talks on structure-based drug design from Lead Pharma, Sanofi, Novartis and Heptares Therapeutics
TOP SPEAKER LINE-UP INCLUDES:
• Andreas Bender, Lecturer for Molecular, Informatics, University of Cambridge - CONFERENCE CHAIR
• Dr Hugo Gutierrez de Teran, Senior Researcher, Division of Computational and Systems Biology, Uppsala University - CONFERENCE CHAIR
• Gary Tresadern, Principal Scientist, Computational Chemistry, Lead Discovery, Janssen Research and Development
• Henrik Moebitz, Investigator, Novartis
• Sudharsan Sridharan, Scientist, MedImmune Ltd
• Gianni Chessari, Director, Computational Chemistry, Astex Pharmaceuticals
• Oliver Plettenburg, Head of Biosensors & Chemical Probes, Sanofi
• Michael Overduin, Professor of Structural Biology, University of Birmingham
• Dr Zara Sands, Principal Scientist, Medicinal Chemistry, UCB BioPharma
• Richard Lewis, Executive Director, Computer-Aided Drug Design, Novartis
Join us as we ask questions such as: What are the key challenges in biotherapeutics discovery? How have computational and predictive tools matured for the application of drug discovery? Are there novel ways to inhibit kinase targets? How can we successfully apply ligand-based and structure based computational approaches for the rational design of novel GPCR antagonists? What are the best approaches in building a robust technology pipeline for robust fragment based drug discovery?
Hear case study driven presentations from an array of market leaders such as the University of Cambridge, Janssen, MedImmune, Sanofi and Novartis, discussing computational approaches, structure based drug design, pharmacokinetics, polypharmacology, drug metabolism and fragment based drug design, PLUS MUCH MORE!
KEY REASONS TO JOIN:
• DISCUSS the application of computational based drug design with five presentations focusing on modelling and engineering
• JOIN the panel discussion on computational and predictive tools for the application of drug discovery
• ENHANCE your understanding of fragment-based drug design by listening to presentations led by UCB Pharmaceuticals, Astex Pharmaceuticals, ZoBio and the University of Birmingham
• LISTEN to talks on structure-based drug design from Lead Pharma, Sanofi, Novartis and Heptares Therapeutics
TOP SPEAKER LINE-UP INCLUDES:
• Andreas Bender, Lecturer for Molecular, Informatics, University of Cambridge - CONFERENCE CHAIR
• Dr Hugo Gutierrez de Teran, Senior Researcher, Division of Computational and Systems Biology, Uppsala University - CONFERENCE CHAIR
• Gary Tresadern, Principal Scientist, Computational Chemistry, Lead Discovery, Janssen Research and Development
• Henrik Moebitz, Investigator, Novartis
• Sudharsan Sridharan, Scientist, MedImmune Ltd
• Gianni Chessari, Director, Computational Chemistry, Astex Pharmaceuticals
• Oliver Plettenburg, Head of Biosensors & Chemical Probes, Sanofi
• Michael Overduin, Professor of Structural Biology, University of Birmingham
• Dr Zara Sands, Principal Scientist, Medicinal Chemistry, UCB BioPharma
• Richard Lewis, Executive Director, Computer-Aided Drug Design, Novartis
Visitors
Advances and Progress in Drug Design 2015 will gather a global audience of industry professionals and leading scientists involved in computational chemistry, lead discovery and structural biology.
Exhibitors
For sponsorship please contact Alia Malick on Tel: +44 (0) 207 827 6168 / Email: amalick@smi-online.co.uk
EIN News
provides powerful, real-time media monitoring, news aggregation & syndication services. Read the latest news about this topic. See:
- Autism News Today
- Brain Cancer News Today
- Brazil Business Today
- Breast Cancer News Today
- Breastfeeding News Today
- CNES News Today
- Canadian Space Agency News Today
- Central Europe Online
- Conferences & Trade Shows Today
- Dental Industry Today
- Dietary Supplements News Today
- H1N1 News Today
- H7N9 Bird Flu News Today
- Health Insurance Exchanges News
- Healthcare Industry Today
- Healthcare Reform News Today
- Home Birth News Today
- Inside China Today
- JAXA News Today
- Lung Cancer News Today
- MERS News Today
- Malaria News Today
- Marijuana News Today
- Mesothelioma News Today
- NASA News Today
- Pharmaceutical Industry Today
- Planned Parenthood News Today
- Prostate Cancer News Today
- Research Reports News Today
- SARS News Today
- Science News Today
- Sea Piracy News Today
- The Russia News Service
- Trans-Pacific Partnership News Today
- Wellness News Today
- World News Report